Drug firm Suven Life Sciences today said it has received four product patents for its new chemical entities (NCEs), which could be used in the treatment of various central nervous system disorders.
The four product patents, one from Europe, two from Sri Lanka and one from Korea, are valid through 2027, 2025 and 2024, respectively, Suven Life Sciences said in a statement.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders, which has an estimated USD 30 billion market potential globally," Suven Life Sciences CEO Venkat Jasti said.
The company has received the approval for molecules that could be used in the treatment of CNS disorders like Parkinson's, Alzheimer's and Schizophrenia, Suven said.
Products out of these inventions may be out-licenced at various phases of clinical development, like Phase-I or Phase-II, it added.
With these new patents, the company has a total of 11 patents from Europe, eight patents from Sri Lanka and five patents from Korea, Suven said.
Shares of Suven Life Sciences were being quoted at Rs 17.50 a piece in afternoon trade on the Bombay Stock Exchange (BSE) today, up 1.45% from their previous close.
